Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Juxtapid Maker Gets FDA Warning Letter Over Misleading Statements November 12, 2013 Martha Garcia Add Your Comments The FDA has issued a warning letter to Aegerion Pharmaceuticals, accusing the company of exaggerating the benefits of Juxtapid and promoting the heart medication for unapproved uses. The FDA warning letter alleges Juxtapid was branded as a drug used to prevent heart attacks and extend the life of the patient. The statements “misleadingly suggest it is safe and effective as monotherapy,” said the FDA letter, for which it is not approved. Juxtapid (lomitapide) is approved for the use of homozygous familial hypercholesterolemia (HoFH), a rare form of high cholesterol which can lead to heart attack and early death. Do You Know about… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… SPORTS BETTING ADDICTION LAWSUITS FOR YOUNG ADULTS Gambling addiction and severe financial losses have been linked to popular sports betting platforms like DraftKings, FanDuel, and Caesars. Lawsuits are being filed by young adults and students who were targeted by deceptive promotions, addictive app features, and aggressive marketing tactics. See if you qualify for a sports betting addiction lawsuit. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The warning letter was issued in response to two television appearances this year by Aegerion’s CEO, Marc Beer, on CNBC’s ‘Fast Money.’ During the broadcasts Beer made statements about Juxtapid, indicating that the drug could increase a person’s life and protect against heart attack in people who suffer from HoFH. Beer made several statements asserting the safety and use of Juxtapid as a prevention for heart attack and early death. “These patients are going to die of a cardiac event, either a stroke or a heart attack, if we don’t have them on therapy,” said Beer during one of the broadcasts. The FDA cites the product labeling in the letter, saying it “is not known if Juxtapid is safe in people with high cholesterol, but who do not have HoFH” and “the effect of the drug on cardiovascular morbidity and mortality has not been determined.” Federal officials chastise Beer’s statements, which seem to be in direct contradiction with product labeling concerning the drug. FDA Questions Juxtapid Marketing Goals The Office of Prescription Drug Promotion (OPDP) of the FDA indicated that the statements made during the June 5 and October 31 broadcasts suggested the drug is intended for new uses, for which it is not approved. These statements place Juxtapid in violation of the Federal Food Drug and Cosmetic Act. The FDA indicates that Beer’s statement that the product has the “potential of taking a patient that would die at 30 and allow them to meet their grandkids,” is misleading to patients. The FDA is also concerned the company did not adequately communicate the drugs risks to patients and misrepresented those risks during television broadcasts and in other product marketing. Severe risks include liver toxicity, risk of embryo fetal-toxicity, reduced absorption of fat soluble vitamins, diarrhea, nausea, vomiting and abdominal pain. The product is only approved as an adjunct to a low-fat diet and other cholesterol lowering treatments. The FDA did not approve it for stand-alone use. The FDA is requesting a written response from Aegerion by November 22, to ensure the company will correct any misbranding or false statements made about Juxtapid’s efficacy. The FDA warned the company that if monotherapy is the goal of the medication then its distribution is illegal, since the FDA never approved it for that use. The FDA warned that a failure to respond to the charges could lead to product seizure and injunction. Tags: Aegerion Pharmaceuticals, Cholesterol, Cholesterol Drug, Heart Attack, Juxtapid More Lawsuit Stories Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks June 20, 2025 Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions June 20, 2025 New Study Links Ultra-Processed Foods Intake With Multiple Adverse Health Effects June 20, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: yesterday) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025) Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 3 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024) Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 4 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)
Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: yesterday) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025)
Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 3 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024)
Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 4 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)